Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sector Strengthened IP with patent filing for use of rare cannabinoids for the treatment… Read More
PROpel Is the First Phase 3 Trial to Show Clinical Benefit in Radiographic Progression-Free Survival With a PARP Inhibitor in This Setting KENILWORTH, N.J. — AstraZeneca and Merck (NYSE: MRK),… Read More
Vancouver, BC — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of… Read More
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other… Read More
WHO’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countries Since the beginning of the pandemic, more than one… Read More
